MedMira’s COVID-19 Tests – for ANY STAGE

Download the MedMira COVID-19 testing overview
Update on Validation of VYRA™ CoV2Flu

By analyzing the mutation sites of N protein and their proportion according to the coronavirus sequences released by the GISAID database, full-length N protein recombinant antigens corresponding to VOC(Variants of Concern) and other mutant strains have been obtained as a mean to validate the current VYRA™ CoV2Flu antigen test’s sensitivity. The testing variants includes: Omicron […]
MedMira Announces VYRA™ CoV2Flu and Additional Regulatory Opportunities

Halifax, Nova Scotia, 21 December, 2021 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the expansion of its VYRATMproduct line by launching its VYRA™ CoV2Flu Rapid Antigen Rapid Test (VYRA™ CoV2Flu). Based on MedMira’s proprietary technology, this 3-in-1 test is developed to distinguish between SARS-CoV-2 and Influenza A or B infections. Furthermore, the Company takes […]